1	WHO. World health statistics 2022: monitoring health for the SDGs, sustainable development goals[M]. Geneva: World Health Organization, 2022. 本文引用 [1]

2	JENG WJ, PAPATHEODORIDIS GV, LOK A. Hepatitis B[J]. Lancet, 2023, 401(10381): 1039-1052. DOI: 10.1016/S0140-6736(22)01468-4 . 本文引用 [1]

3

Chinese Society of Infectious Disease, Chinese Society of Hepatology, Chinese Medical Association. The expert consensus on functional cure of chronic hepatitis B[J]. J Clin Hepatol, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008 . 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 临床肝胆病杂志, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008 . 本文引用 [1]

4	LI MH, SUN FF, BI XY, et al. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients[J]. Virol Sin, 2022, 37(3): 390-397. DOI: 10.1016/j.virs.2022.03.001 . 本文引用 [2]

5	GAO N, YU HY, ZHANG J, et al. Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon-based therapy[J]. J Viral Hepat, 2022, 29(10): 899-907. DOI: 10.1111/jvh.13734 . 本文引用 [3]

6	HUANG D, WU D, WANG P, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB[J]. J Hepatol, 2022, 77(1): 42-54. DOI: 10.1016/j.jhep.2022.01.021 . 本文引用 [2]

7	LOK AS, ZOULIM F, DUSHEIKO G, et al. Durability of hepatitis B surface antigen loss with nucleotide analogue and peginterferon therapy in patients with chronic hepatitis B[J]. Hepatol Commun, 2019, 4(1): 8-20. DOI: 10.1002/hep4.1436 . 本文引用 [1]

8

GHANY MG, BUTI M, LAMPERTICO P, et al. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV treatment endpoints conference[J]. J Hepatol, 2023, 79(5): 1254-1269. DOI: 10.1016/j.jhep.2023.06.002 . 本文引用 [5]

9	CORNBERG M, LOK AS, TERRAULT NA, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B-report from the 2019 EASL-AASLD HBV treatment endpoints conference(double dagger)[J]. J Hepatol, 2020, 72(3): 539-557. DOI: 10.1016/j.jhep.2019.11.003 . 本文引用 [1]

10	YIP TCF, WONG GLH, CHAN HLY, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues[J]. J Hepatol, 2019, 70(3): 361-370. DOI: 10.1016/j.jhep.2018.10.014 . 本文引用 [1]

11	XIE C, XIE D, XU Q, et al. The everest project's 5-year update: efficacy of PEG-IFNα therapy in NA-suppressed HBeAg negative CHB[R]. Kyoto: APASL, 2024. 本文引用 [1]

12	HU P, SHANG J, ZHANG WH, et al. HBsAg loss with peg-interferon Alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: New switch study[J]. J Clin Transl Hepatol, 2018, 6(1): 25-34. DOI: 10.14218/JCTH.2017.00072 .

13	VITTAL A, SHARMA D, HU A, et al. Systematic review with meta-analysis: The impact of functional cure on clinical outcomes in patients with chronic hepatitis B[J]. Aliment Pharmacol Ther, 2022, 55(1): 8-25. DOI: 10.1111/apt.16659 . 本文引用 [1]

14	HU Y, YE YZ, YE LJ, et al. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: A real-life cohort study from Shanghai, China[J]. World J Pediatr, 2019, 15(6): 595-600. DOI: 10.1007/s12519-019-00303-w . 本文引用 [1]

15

ZHONG WT, YAN LZ, ZHU YG, et al. A high functional cure rate was induced by pegylated interferon alpha-2b treatment in postpartum hepatitis B e antigen-negative women with chronic hepatitis B virus infection: An exploratory study[J]. Front Cell Infect Microbiol, 2024, 14: 1426960. DOI: 10.3389/fcimb.2024.1426960 . 本文引用 [1]

16

TU T, BUDZINSKA MA, VONDRAN FWR, et al. Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via sodium taurocholate cotransporting polypeptide-dependent uptake of enveloped virus particles[J]. J Virol, 2018, 92(11): e02007-17. DOI: 10.1128/JVI.02007-17 . 本文引用 [1]

17	TU T, BUDZINSKA MA, SHACKEL NA, et al. HBV DNA integration: Molecular mechanisms and clinical implications[J]. Viruses, 2017, 9(4): 75. DOI: 10.3390/v9040075 . 本文引用 [2]

18	TU T, ZEHNDER B, QU BQ, et al. De novo synthesis of hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA[J]. JHEP Rep, 2020, 3(1): 100195. DOI: 10.1016/j.jhepr.2020.100195 . 本文引用 [1]

19	CHUA CG, MEHROTRA A, MAZZULLI T, et al. Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patients[J]. Sci Rep, 2020, 10(1): 11344. DOI: 10.1038/s41598-020-68226-5 . 本文引用 [1]

20	MASON WS, GILL US, LITWIN S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant[J]. Gastroenterology, 2016, 151(5): 986-998. e4. DOI: 10.1053/j.gastro.2016.07.012 . 本文引用 [1]

21	MEIER MA, CALABRESE D, SUSLOV A, et al. Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load[J]. J Hepatol, 2021, 75(4): 840-847. DOI: 10.1016/j.jhep.2021.04.051 . 本文引用 [1]

22	RINGLANDER J, SKOGLUND C, PRAKASH K, et al. Deep sequencing of liver explant transcriptomes reveals extensive expression from integrated hepatitis B virus DNA[J]. J Viral Hepat, 2020, 27(11): 1162-1170. DOI: 10.1111/jvh.13356 . 本文引用 [1]

23	TU T, ZHANG H, URBAN S. Hepatitis B virus DNA integration: in vitro models for investigating viral pathogenesis and persistence[J]. Viruses, 2021, 13(2): 180. DOI: 10.3390/v13020180 . 本文引用 [2]

24	VAILLANT A. HBsAg, subviral particles, and their clearance in establishing a functional cure of chronic hepatitis B virus infection[J]. ACS Infect Dis, 2021, 7(6): 1351-1368. DOI: 10.1021/acsinfecdis.0c00638 . 本文引用 [1]

25	THIBAULT V, SERVANT-DELMAS A, LY TD, et al. Performance of HBsAg quantification assays for detection of hepatitis B virus genotypes and diagnostic escape-variants in clinical samples[J]. J Clin Virol, 2017, 89: 14-21. DOI: 10.1016/j.jcv.2017.02.001 . 本文引用 [2]

26	YAN Y, SUN HZ, CHANG L, et al. Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection[J]. Front Microbiol, 2022, 13: 1063616. DOI: 10.3389/fmicb.2022.1063616 . 本文引用 [3]

27	ANDERSON M, HOLZMAYER V, STEC M, et al. Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes: Considerations for new and existing therapies[J]. J Hepatol, 2024, 81(1): e24-e25. DOI: 10.1016/j.jhep.2023.11.018 . 本文引用 [5]

28	WONG DKH, CHEN C, MAK LY, et al. Detection of the hepatitis B surface antigen in patients with occult hepatitis B by use of an assay with enhanced sensitivity[J]. J Clin Microbiol, 2022, 60(2): e0220421. DOI: 10.1128/jcm.02204-21 . 本文引用 [2]

29	KUSUMOTO S, TANAKA Y, SUZUKI R, et al. Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma[J]. J Hepatol, 2020, 73(2): 285-293. DOI: 10.1016/j.jhep.2020.03.009 . 本文引用 [1]

30	GHANY MG, BUTI M, LAMPERTICO P, et al. Reply to: “ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes: Considerations for new and existing therapies”[J]. J Hepatol, 2024, 81(1): e26-e27. DOI: 10.1016/j.jhep.2024.03.001 . 本文引用 [1]

31	MAK LY, WONG DKH, POLLICINO T, et al. Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance[J]. J Hepatol, 2020, 73(4): 952-964. DOI: 10.1016/j.jhep.2020.05.042 . 本文引用 [2]

32	XIANG KH, MICHAILIDIS E, DING H, et al. Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA[J]. J Hepatol, 2017, 66(2): 288-296. DOI: 10.1016/j.jhep.2016.09.005 . 本文引用 [2]

33	DEGUCHI M, YAMASHITA N, KAGITA M, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay[J]. J Virol Methods, 2004, 115(2): 217-222. DOI: 10.1016/j.jviromet.2003.10.002 .

34	LEE HJ, KIM SY, LEE SM, et al. Elecsys hepatitis B surface antigen quantitative assay: Performance evaluation and correlation with hepatitis B virus DNA during 96 weeks of follow-up in chronic hepatitis B patients[J]. Ann Lab Med, 2012, 32(6): 420-425. DOI: 10.3343/alm.2012.32.6.420 . 本文引用 [1]

35	THIBAULT V, LAPERCHE S, AKHAVAN S, et al. Impact of hepatitis B virus genotypes and surface antigen variants on the performance of HBV real time PCR quantification[J]. J Virol Methods, 2009, 159(2): 265-270. DOI: 10.1016/j.jviromet.2009.04.014 . 本文引用 [1]

36	VERHEYEN J, NEUMANN-FRAUNE M, BERG T, et al. The detection of HBsAg mutants expressed in vitro using two different quantitative HBsAg assays[J]. J Clin Virol, 2012, 54(3): 279-281. DOI: 10.1016/j.jcv.2012.04.010 . 本文引用 [2]

37	WILKINSON DE, SEIZ PL, SCHÜTTLER CG, et al. International collaborative study on the 3rd WHO International Standard for hepatitis B surface antigen[J]. J Clin Virol, 2016, 82: 173-180. DOI: 10.1016/j.jcv.2016.06.003 . 本文引用 [1]

38	WANG ZL, ZHENG JR, YANG RF, et al. An ideal hallmark closest to complete cure of chronic hepatitis B patients: High-sensitivity quantitative HBsAg loss[J]. J Clin Transl Hepatol, 2023, 11(1): 197-206. DOI: 10.14218/JCTH.2022.00289 . 本文引用 [1]

39	PFEFFERKORN M, BÖHM S, SCHOTT T, et al. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers[J]. Gut, 2018, 67(11): 2045-2053. DOI: 10.1136/gutjnl-2017-313811 . 本文引用 [1]

40	LIN X, ZHENG YH, LI H, et al. Serum hepatitis B virus large and medium surface proteins as novel tools for predicting HBsAg clearance[J]. Front Immunol, 2022, 13: 1028921. DOI: 10.3389/fimmu.2022.1028921 . 本文引用 [1]

41	PFEFFERKORN M, SCHOTT T, BÖHM S, et al. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B[J]. J Hepatol, 2021, 74(2): 283-292. DOI: 10.1016/j.jhep.2020.08.039 . 本文引用 [2]

42	PFEFFERKORN M, van BÖMMEL F. Commentary: Serum hepatitis B virus large and medium surface proteins as novel tools for predicting HBsAg clearance[J]. Front Immunol, 2022, 13: 1081730. DOI: 10.3389/fimmu.2022.1081730 . 本文引用 [1]

43

LU JH, YANG L, ZHAO ZX, et al. Comparative study of high? sensitivity and conventional fluorescence quantitative PCR in the monitoring of antiviral efficacy in patients with chronic hepatitis B[J]. J Mol Diagn Ther, 2019, 11(5): 361-364. DOI: 10.3969/j.issn.1674-6929.2019.05.005 . 卢建华, 杨莉, 赵召霞, 等. 高敏与普通荧光定量PCR技术在慢乙肝患者抗病毒疗效监测中的对比研究[J]. 分子诊断与治疗杂志, 2019, 11(5): 361-364. DOI: 10.3969/j.issn.1674-6929.2019.05.005 . 本文引用 [1]

44

FENG B, ZHENG JR, WANG ZL. Clinical value of highly sensitive hepatitis B virus surface antigen and DNA assays[J]. Chin J Lab Med, 2023, 46(1): 7-11. DOI: 10.3760/cma.j.cn114452-20220817-00475 . 封波, 郑佳睿, 王资隆. 高灵敏乙型肝炎病毒表面抗原和DNA检测的临床应用价值[J]. 中华检验医学杂志, 2023, 46(1): 7-11. DOI: 10.3760/cma.j.cn114452-20220817-00475 . 本文引用 [1]

45	INOUE T, KUSUMOTO S, IIO E, et al. Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation[J]. J Hepatol, 2021, 75(2): 302-310. DOI: 10.1016/j.jhep.2021.02.017 . 本文引用 [1]

46	WONG DKH, HUANG FY, LAI CL, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma[J]. Hepatology, 2011, 54(3): 829-836. DOI: 10.1002/hep.24551 . 本文引用 [1]

47	GAO N, GUAN GW, XU GL, et al. Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg-positive patients with functional cure following PEG-IFN-based therapy[J]. Aliment Pharmacol Ther, 2023, 58(10): 1086-1098. DOI: 10.1111/apt.17670 . 本文引用 [6]

48	YU XQ, GONG QM, YU DM, et al. Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss[J]. Gut, 2024, 73(5): 797-809. DOI: 10.1136/gutjnl-2023-330577 . 本文引用 [1]

49	NARMADA BC, KHAKPOOR A, SHIRGAONKAR N, et al. Single-cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity[J]. J Hepatol, 2024, 81(1): 42-61. DOI: 10.1016/j.jhep.2024.02.017 . 本文引用 [1]

50	GU ZQ, JIANG QQ, ABULAITI A, et al. Hepatitis B virus enhancer 1 activates preS1 and preS2 promoters of integrated HBV DNA impairing HBsAg secretion[J]. JHEP Rep, 2024, 6(9): 101144. DOI: 10.1016/j.jhepr.2024.101144 . 本文引用 [2]

51	LIANG YJ, TENG W, CHEN CL, et al. Clinical implications of HBV PreS/S mutations and the effects of PreS2 deletion on mitochondria, liver fibrosis, and cancer development[J]. Hepatology, 2021, 74(2): 641-655. DOI: 10.1002/hep.31789 . 本文引用 [1]

52	MICHLER T, ZILLINGER J, HAGEN P, et al. The lack of HBsAg secretion does neither facilitate induction of antiviral T cell responses nor hepatitis B virus clearance in mice[J]. Antiviral Res, 2024, 226: 105896. DOI: 10.1016/j.antiviral.2024.105896 . 本文引用 [1]

53	YANG SS, ZENG WJ, ZHANG JM, et al. Restoration of a functional antiviral immune response to chronic HBV infection by reducing viral antigen load: If not sufficient, is it necessary?[J]. Emerg Microbes Infect, 2021, 10(1): 1545-1554. DOI: 10.1080/22221751.2021.1952851 . 本文引用 [1]

54	WERLE-LAPOSTOLLE B, BOWDEN S, LOCARNINI S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy[J]. Gastroenterology, 2004, 126(7): 1750-1758. DOI: 10.1053/j.gastro.2004.03.018 . 本文引用 [1]

55	CHEVALIEZ S, HÉZODE C, BAHRAMI S, et al. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely[J]. J Hepatol, 2013, 58(4): 676-683. DOI: 10.1016/j.jhep.2012.11.039 . 本文引用 [1]

56	HUANG Q, ZHOU B, CAI DW, et al. Rapid turnover of hepatitis B virus covalently closed circular DNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients[J]. Hepatology, 2021, 73(1): 41-52. DOI: 10.1002/hep.31240 . 本文引用 [1]

57

LU FM, FENG B, ZHENG SJ, et al. Current status of the research on low-level viremia in chronic hepatitis B patients receiving nucleos(t)ide analogues[J]. J Clin Hepatol, 2021, 37(6): 1268-1274. DOI: 10.3969/j.issn.1001-5256.2021.06.007 . 鲁凤民, 封波, 郑素军, 等. 核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究现状[J]. 临床肝胆病杂志, 2021, 37(6): 1268-1274. DOI: 10.3969/j.issn.1001-5256.2021.06.007 . 本文引用 [1]

58	ALLWEISS L, VOLZ T, GIERSCH K, et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo[J]. Gut, 2018, 67(3): 542-552. DOI: 10.1136/gutjnl-2016-312162 . 本文引用 [1]

59	WANG Y, LI YM, ZAI WJ, et al. HBV covalently closed circular DNA minichromosomes in distinct epigenetic transcriptional states differ in their vulnerability to damage[J]. Hepatology, 2022, 75(5): 1275-1288. DOI: 10.1002/hep.32245 . 本文引用 [1]

60	MICHLER T, KOSINSKA AD, FESTAG J, et al. Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice[J]. Gastroenterology, 2020, 158(6): 1762-1775. e9. DOI: 10.1053/j.gastro.2020.01.032 . 本文引用 [1]

61	IANNACONE M, GUIDOTTI LG. Immunobiology and pathogenesis of hepatitis B virus infection[J]. Nat Rev Immunol, 2022, 22(1): 19-32. DOI: 10.1038/s41577-021-00549-4 .

62	ZHENG PY, DOU YQ, WANG QY. Immune response and treatment targets of chronic hepatitis B virus infection: Innate and adaptive immunity[J]. Front Cell Infect Microbiol, 2023, 13: 1206720. DOI: 10.3389/fcimb.2023.1206720 . 本文引用 [2]

63	FAURE-DUPUY S, DELPHIN M, AILLOT L, et al. Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection[J]. J Hepatol, 2019, 71(6): 1086-1098. DOI: 10.1016/j.jhep.2019.06.032 . 本文引用 [1]

64	GUAN GW, ZHANG T, NING J, et al. Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-α-treated patients with chronic hepatitis B[J]. J Hepatol, 2024, 80(1): 41-52. DOI: 10.1016/j.jhep.2023.09.039 . 本文引用 [1]

65	CHEN HT, SUN J, ZHOU B, et al. Variants in STAT4 associated with cure of chronic HBV infection in HBeAg-positive patients treated with pegylated interferon-alpha[J]. Clin Gastroenterol Hepatol, 2020, 18(1): 196-204. e8. DOI: 10.1016/j.cgh.2019.04.044 . 本文引用 [1]

66	WU TT, COATES L, ALDRICH CE, et al. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway[J]. Virology, 1990, 175(1): 255-261. DOI: 10.1016/0042-6822(90)90206-7 . 本文引用 [1]

67	ZOULIM F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA[J]. J Hepatol, 2005, 42(3): 302-308. DOI: 10.1016/j.jhep.2004.12.015 . 本文引用 [1]

68	YUEN MF, AGARWAL K, GANE EJ, et al. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: A randomised, placebo-controlled phase 1 trial[J]. Lancet Gastroenterol Hepatol, 2020, 5(2): 152-166. DOI: 10.1016/S2468-1253(19)30346-2 . 本文引用 [1]

69

YUEN MF, ZHOU X, GANE E, et al. Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: A multicentre, randomised, placebo-controlled, phase 1 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(9): 723-732. DOI: 10.1016/S2468-1253(21)00176-X . 本文引用 [1]

70	CHENG DL, HAN B, ZHANG W, et al. Clinical effects of NTCP-inhibitor myrcludex B[J]. J Viral Hepat, 2021, 28(6): 852-858. DOI: 10.1111/jvh.13490 . 本文引用 [1]

71	WANG L, ZHU QH, ZHANG JD, et al. Discovery of a first-in-class orally available HBV cccDNA inhibitor[J]. J Hepatol, 2023, 78(4): 742-753. DOI: 10.1016/j.jhep.2022.12.014 . 本文引用 [1]

72	PONDÉ RAA, AMORIM GSP. Elimination of the hepatitis B virus: A goal, a challenge[J]. Med Res Rev, 2024, 44(5): 2015-2034. DOI: 10.1002/med.22030 . 本文引用 [1]

73	LIM SG, BAUMERT TF, BONI C, et al. The scientific basis of combination therapy for chronic hepatitis B functional cure[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(4): 238-253. DOI: 10.1038/s41575-022-00724-5 . 本文引用 [1]

74	LEE MH, YANG HI, LIU J, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles[J]. Hepatology, 2013, 58(2): 546-554. DOI: 10.1002/hep.26385 . 本文引用 [3]

75	TSENG TC, LIU CJ, CHEN CL, et al. Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers[J]. J Infect Dis, 2013, 208(4): 584-593. DOI: 10.1093/infdis/jit209 . 本文引用 [1]

76	BRANCACCIO G, SALPINI R, PIERMATTEO L, et al. An increase in the levels of middle surface antigen characterizes patients developing HBV-driven liver cancer despite prolonged virological suppression[J]. Microorganisms, 2021, 9(4): 752. DOI: 10.3390/microorganisms9040752 . 本文引用 [1]

77	SONNEVELD MJ, CHIU SM, PARK JY, et al. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels[J]. J Hepatol, 2022, 76(5): 1042-1050. DOI: 10.1016/j.jhep.2022.01.007 . 本文引用 [1]

78	TSENG CH, CHEN TH, WU JL, et al. Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis[J]. JHEP Rep, 2022, 5(1): 100617. DOI: 10.1016/j.jhepr.2022.100617 . 本文引用 [1]

79	WEN CJ, WANG YX, TIAN HY, et al. Clinical cure induced by pegylated interferon α‍-2b in the advantaged population of chronic hepatitis B virus infection: A retrospective cohort study[J]. Front Cell Infect Microbiol, 2024, 13: 1332232. DOI: 10.3389/fcimb.2023.1332232 . 本文引用 [1]